Maze Therapeutics Financial Ratios
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
27.11+1.23 (+4.75%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics ratio analysis
Return on equity reached -36.9%, meaning Maze Therapeutics generated -0.37 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 |
|---|---|---|
| Price / book | 4.81 | — |
| Operating margin | — | 34.4% |
| Net margin | — | 31.2% |
| Free cash flow margin | — | 44.7% |
| Return on equity (ROE) | -36.9% | — |
| Return on assets (ROA) | -33.0% | 21.7% |
| Current ratio | 15.50 | 9.76 |
| EPS growth | -344.0% | — |